Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2D | O15399 | 4/20 | 0.36 |
| ▸ | GRIN3B | O60391 | 4/20 | 0.36 |
| ▸ | GRIN1 | Q05586 | 4/20 | 0.36 |
| ▸ | GRIN2A | Q12879 | 4/20 | 0.36 |
| ▸ | GRIN2B | Q13224 | 4/20 | 0.36 |
| ▸ | GRIN2C | Q14957 | 4/20 | 0.36 |
| ▸ | GRIN3A | Q8TCU5 | 4/20 | 0.36 |
| ▸ | PTGDR | Q13258 | 13/20 | 0.32 |
| ▸ | TBXA2R | P21731 | 9/20 | 0.32 |
| ▸ | PDE2A | O00408 | 7/20 | 0.32 |
| ▸ | PDE4A | P27815 | 1/20 | 0.32 |
| ▸ | TSPO | P30536 | 1/20 | 0.32 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.32 |
| ▸ | DRD3 | P35462 | 1/20 | 0.32 |
| ▸ | PTGFR | P43088 | 1/20 | 0.32 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.32 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.32 |
| ▸ | PTGIR | P43119 | 1/20 | 0.32 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.32 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5774572 | 0.83 | PTGDR (0.44) | PTGDRTBXA2RPDE2APDE4ATSPO | |
| SCHEMBL5775908 | 0.83 | PTGDR (0.44) | PTGDRTBXA2RPDE2APDE4ATSPO | |
| SCHEMBL5778075 | 0.83 | GRIN2D (0.39) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL2922358 | 0.81 | GRIN2D (0.34) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL1254302 | 0.79 | — | — | |
| SCHEMBL5777134 | 0.78 | FFAR4 (0.35) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL5776227 | 0.77 | PDE2A (0.34) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL5772697 | 0.73 | TBXA2R (0.37) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL28527343 | 0.69 | GRIN2D (0.38) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL5776905 | 0.68 | PTGDR (0.42) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2116244-B1 | Method of treating atherosclerosis, dyslipidemias and related conditions | SCHERING CORP (US) | 2012-08-08 | — | — | EP | disclosed |
| EP-1558614-B1 | PYRIDOPYRROLIZINE AND PYRIDOINDOLIZINE DERIVATIVES | MERCK FROSST CANADA LTD (CA) | 2010-09-01 | — | — | EP | disclosed |
| US-20100076002-A1 | Method of Treating Atherosclerosis, Dyslipidemias and Related Conditions and Pharmaceutical Compositions | CHENG KANG | 2010-03-25 | — | — | US | disclosed |
| US-7618979-B2 | Pyridopyrrolizine and pyridoindolizine derivatives | MERCK FROSST CANADA LTD. (CA) | 2009-11-17 | — | — | US | disclosed |
| EP-2116244-A1 | Method of treating atherosclerosis, dyslipidemias and related conditions | Merck & Co., Inc. (US) | 2009-11-11 | — | — | EP | disclosed |
| US-20070299122-A1 | Method of Treating Pathological Blushing | MERCK SHARP & DOHME CORP. | 2007-12-27 | — | — | US | disclosed |
| US-20070299101-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | MERCK SHARP & DOHME CORP. | 2007-12-27 | — | — | US | disclosed |
| US-20070281969-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | MERCK SHARP & DOHME CORP. | 2007-12-06 | — | — | US | disclosed |
| US-20070244107-A1 | Method of Treating Atherosclerosis, Dyslipidemias and Related Conditions | MERCK & CO., INC. | 2007-10-18 | — | — | US | disclosed |
| WO-2006052798-A2 | METHOD OF TREATING PATHOLOGICAL BLUSHING | MERCK & CO., INC. (US) | 2006-05-18 | — | — | WO | disclosed |
| US-20050272756-A1 | Pyridopyrrolizine and pyridoindolizine derivatives | MERCK CANADA INC. (CA) | 2005-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050272756-A1 | Pyridopyrrolizine and pyridoindolizine derivatives | PTGIR, PTGIS, PTGES | GRIN2D 2167/4885GRIN3B 3171/4885GRIN1 2510/4885 |
| US-20070299122-A1 | Method of Treating Pathological Blushing | BDKRB2, BDKRB1, PTGIR | GRIN2D 1985/4885GRIN3B 597/4885GRIN1 1262/4885 |
| US-20070281969-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | GPR119, FFAR1, HCAR1 | GRIN2D 1997/4885GRIN3B 1143/4885GRIN1 1078/4885 |
| US-20100076002-A1 | Method of Treating Atherosclerosis, Dyslipidemias and Related Conditions and Pharmaceutical Compositions | LDLR, LPAR5, FFAR1 | GRIN2D 1858/4885GRIN3B 862/4885GRIN1 601/4885 |
| US-20070299101-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | LDLR, APOB, FFAR1 | GRIN2D 2451/4885GRIN3B 1163/4885GRIN1 1142/4885 |
| US-20070244107-A1 | Method of Treating Atherosclerosis, Dyslipidemias and Related Conditions | LDLR, LIPA, APOB | GRIN2D 3388/4885GRIN3B 1744/4885GRIN1 1387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.